MLH1 and Li-Fraumeni syndrome: Thus, testing began with TP53 in 1990 following its identification as being causative of Li Fraumeni Syndrome in 1990 [6], followed by APC in 1993, then BRCA1 in 1994 and BRCA2, MLH1 and MSH2 in 1996.